In patients with neuroendocrine tumors (NETs), standard of care requires testing of the most important biochemical tumour markers: chromogranin A (CgA, diagnostic sensitivity and specificity within the range of 60-90%) and neuron-specific enolase (NSE) (45). This evidence concerns the gene ENO2 and neuroendocrine neoplasm.